Cleveland Biolabs (CBLI) Stock News

NASDAQ:CBLI - Nasdaq -

3.17 -0.25 (-7.31%)

After market: 3.17 0 (0%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CBLI Latest News, Press Relases and Analysis

All

Press Releases

4 years ago - By: Benzinga - Mentions: AMZN CVS WBA STAB

Possibly Groundbreaking Studies to Be Conducted on the Effectiveness of Short and Long-term COVID-19 Therapies Inhibiting the Progression of SARS-CoV-2

4 years ago - By: Benzinga - Mentions: STAB

What is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease and Autoimmune Disorders?

4 years ago - By: Cytocom, Inc.

Cytocom, Inc. Announces Plan to Adopt New Corporate Name "Statera BioPharma, Inc."

4 years ago - By: BusinessInsider

Cytocom, Inc. Second Quarter 2021 Financial Results Conference Call Replay Available Via Webcast

4 years ago - By: Cytocom, Inc.

Cytocom, Inc. Second Quarter 2021 Financial Results Conference Call Replay Available Via Webcast

4 years ago - By: Analyst Ratings

News Image

The CMO of Cleveland Biolabs (NASDAQ: CBLI) is Buying Shares

4 years ago - By: Cytocom Inc.

Cytocom, Inc. Reports Second Quarter 2021 Financial Results

4 years ago - By: Cytocom, Inc.

Cytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance Agreement

4 years ago - By: Cytocom Inc.

Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business Conference

4 years ago - By: BusinessInsider

Cytocom, Inc. to Report Second Quarter 2021 Financial Results

4 years ago - By: Cytocom, Inc.

Cytocom, Inc. to Report Second Quarter 2021 Financial Results

4 years ago - By: Cytocom Inc.

Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn's Disease, Hematology, Pancreatic Cancer and COVID-19

4 years ago - By: Cytocom, Inc.

Cytocom Inc. Provides Update on Completed Merger with Cleveland BioLabs

4 years ago - By: Cytocom, Inc.

Cytocom, Inc. Receives Commitments for $90 Million in Equity and Debt Financing

4 years ago - By: Cytocom, Inc.

Cleveland BioLabs, Inc. and Cytocom Inc. Announce Call to Discuss Stockholder Meeting Vote Results and Proposed Merger

4 years ago - By: Cytocom, Inc.

Cleveland BioLabs, Inc. and Cytocom Announce Registration Statement and Proxy Statement for Previously Announced Merger Declared Effective by SEC

4 years ago - By: Cleveland BioLabs, Inc

Genome Protection Announces Publication of the Next Generation Deimmunized TLR5 Agonist, GP532